Bevacizumab (Avastin) with lomustine for glioblastoma – second line
NIHR HSRIC
Record ID 32016000394
English
Authors' objectives:
Glioblastoma is a form of fast growing brain cancer. Treatment for glioblastoma is often not fully successful, and the cancer often returns.
Bevacizumab is a new drug for the treatment of glioblastomas. Some studies have shown bevacizumab works best in combination with another commonly used drug called lomustine. Bevacizumab is delivered straight into the blood every two weeks, alongside lomustine which is given orally every six weeks.
If bevacizumab with lomustine is licensed for use in the UK, it could be a new treatment option for patients with glioblastoma that may improve survival when current treatments have not worked.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/bevacizumab-avastin-with-lomustine-for-glioblastoma-second-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Glioblastoma
- Lomustine
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.